

IN THE CLAIMS: Please substitute amended Claims 1, 2, 7, 10 and 13, which read as follows:

1. (Amended) A method of decreasing atherosclerosis [and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease] comprising administering to an animal or human an amount of a substance which acts to decrease the levels of testosterone or which inhibits the actions of testosterone.

2. (Amended) A method of decreasing atherosclerosis [and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease] comprising administering to a human or an animal an amount of a substance selected from the group consisting of leuprolide acetate, goserlin acetate, flutamide, bicalutamide and nilutamide, which is an inhibitor of the release of LHRH or GnRH, [or any substance which inhibits the action or effects of LHRH,] resulting in decreased levels of LH (luteinizing hormone).

7. (Amended) A method of Claim 5 wherein [Bicalutamide] bicalutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, [or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis].

10. (Amended) A method of Claim 5 wherein [Flutamide] flutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, [or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis].

13. (Amended) A method of Claim 11 wherein [Nilutamide] nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or